Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
  • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
  • C07D221/04—Ortho- or peri-condensed ring systems
  • C07D221/06—Ring systems of three rings
  • C07D221/10—Aza-phenanthrenes
  • C07D221/12—Phenanthridines

Definitions

• the invention relates to novel 6-alkylphenanthridines which are used in the pharmaceutical industry for the production of medicaments.
• German Patent Application DE 11 99 773 describes the preparation of 6-methyl-8,9-methylenedioxy-1,2,3,4,4a,5,6,10b-octahydrophenanthridine, which should have analgesic, antiinflammatory and anti-pyretic properties.
• Indian Journal of Chemistry 7, 1969, 674-677 the preparation of ethyl 1,2,3,4,4a,10a-hexahydrophenanthridine-6-butyrate is described.
• the invention thus relates to compounds of the formula I
• R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,
• R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,
• R1 and R2 together are a 1-2C-alkylenedioxy group
• R3 is hydrogen or 1-4C-alkyl
• R31 is hydrogen or 1-4C-alkyl
• R3 and R31 together are a 1-4C-alkylene group
• R4 is hydrogen or 1-4C-alkyl
• R5 is hydrogen
• R51 is hydrogen
• A is 1-6C-alkylene or 5-7C-cycloalkylene
• R6 is COOR61 or CON(R62)R63, where
• R61 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl and
• R62 and R63 independently of one another are hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl,
• 1-4C-Alkyl represents a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl and, preferably, the ethyl and methyl radicals.
• 1-4C-Alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and, preferably, the ethoxy and methoxy radicals.
• 3-7C-Cycloalkoxy represents cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cycloheptyloxy, of which cyclopropyloxy, cyclobutyloxy and cyclopentyloxy are preferred.
• 3-7C-Cycloalkylmethoxy represents cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy and cycloheptylmethoxy, of which cyclopropylmethoxy, cyclobutylmethoxy and cyclopentylmethoxy are preferred.
• 1-2C-Alkylenedioxy represents, for example, the methylenedioxy (—O—CH 2 —O—) and the ethylenedioxy radicals (—O—CH 2 —CH 2 —O—).
• R3 and R31 together have the meaning 1-4C-alkylene
• the positions 1 to 4 in compounds of the formula I are linked to one another by a 1-4C-alkylene bridge, 1-4C-alkylene representing straight-chain or branched alkylene radicals having 1 to 4 carbon atoms.
• 1-4C-alkylene representing straight-chain or branched alkylene radicals having 1 to 4 carbon atoms. Examples which may be mentioned are the radicals methylene (—CH 2 —), ethylene (—CH 2 —CH 2 —), trimethylene (—CH 2 —CH 2 —CH 2 —), 1,2-dimethylethylene [—CH(CH 3 )—CH(CH 3 )—] and isopropylidene [—C(CH 3 ) 2 —].
• 1-6C-Alkylene represents straight-chain or branched 1-6C-alkylene radicals, for example the methylene (—CH 2 —), ethylene (—CH 2 —CH 2 —), trimethylene (—CH 2 —CH 2 —CH 2 —), tetramethylene (—CH 2 —CH 2 —CH 2 —CH 2 —), 1,2-dimethyl-ethylene [—CH(CH 3 )—CH(CH 3 )—], 1,1-dimethylethylene [—C(CH 3 ) 2 —CH 2 —], 2,2-dimethylethylene [—CH 2 —C(CH 3 ) 2 —], isopropylidene [—C(CH 3 ) 2 —], 1-methylethylene [—CH(CH 3 )—CH 2 —], pentamethylene (—CH 2 —CH 2 —CH 2 —CH 2 —CH 2 —) and the hexamethylene radicals (—CH 2 —CH 2 —CH 2 —CH 2 —CH
• 5-7C-Cycloalkylene represents cycloalkylene radicals having 5 to 7 carbon atoms. Cyclohexylene radicals are preferred, where, for example, the 1,3- and the 1,4-cyclohexylene radicals may be mentioned.
• 1-7C-Alkyl represents straight-chain or branched alkyl radicals having 1 to 7 carbon atoms. Examples which may be mentioned are the heptyl, isoheptyl (5-methylhexyl), hexyl, isohexyl (4-methylpentyl), neohexyl (3,3-dimethylbutyl), pentyl, isopentyl (3-methylbutyl), neopentyl (2,2-dimethylpropyl), butyl, isobutyl, sec-butyl, tert butyl, propyl, isopropyl, ethyl and methyl radicals.
• 3-7C-Cycloalkyl represents the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl radicals.
• 3-7C-Cycloalkylmethyl represents a methyl radical which is substituded by one of the abovementioned 3-7C-cycloalkyl radicals. Examples which may be mentioned are the cyclopentylmethyl and the cyclohexylmethyl radicals.
• salts with bases are also suitable.
• examples of salts with bases which may be mentioned are alkali metal (lithium, sodium, potassium) or calcium, aluminum, magnesium, titanium, ammonium, meglumine or guanidinium salts, where here too the bases are employed in salt preparation in an equimolar quantitative ratio or one differing therefrom.
• Pharmacologically intolerable salts which may be obtained initially as process products, for example in the preparation of the compounds according to the invention on an industrial scale, are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
• the compounds of the invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of formula I as well as all solvents and in particular all hydrates of the salts of the compounds of formula I.
• R1 is 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy.
• R2 is 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy.
• R3 is hydrogen
• R31 is hydrogen
• R3 and R31 together are a 1-2C-alkylene group
• R4 is hydrogen or 1-4C-alkyl
• R5 is hydrogen
• R51 is hydrogen
• R5 is R51 together are an additional bond
• A is 1-6C-alkylene or 5-7C-cycloalkylene
• R6 is COOR61 or CON(R62)R63, where
• R61 is hydrogen, 1-7C-alkyl or 3-7C-cycloalkylmethyl and
• R62 and R63 independently of one another are hydrogen or 1-7C-alkyl
• R1 is 1-4C-alkoxy, 3-7C-cycloalkoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,
• R2 is 1-4C-alkoxy, 3-7C-cycloalkoxy or completely or predominatly fluorine-substituted 1-2C-alkoxy,
• R3 is hydrogen
• R31 is hydrogen
• R3 and R31 together are a 1-2C-alkylene group
• R4 is hydrogen or 1-4C-alkyl
• R5 is hydrogen
• R51 is hydrogen
• A is 1-6C-alkylene or 5-7C-cycloalkylene
• R6 is COOR61 or CON(R62)R63, where
• R61 is hydrogen, 1-4C-alkyl
• R62 and R63 independently of one another are hydrogen or 1-4C-alkyl
• Preferred compounds of the formula I are those in which
• R1 is 1-2C-alkoxy
• R2 is 1-2C-alkoxy
• R3 is hydrogen
• R31 is hydrogen
• R4 is hydrogen
• R5 is hydrogen
• R51 is hydrogen
• A is cyclohexylene
• R6 is COOR61, where
• R61 is 1-4C-alkyl
• the compounds of the formula I are chiral compounds having chiral centers in the positions 4 a and 10 b and, depending on the meaning of the substituents R3, R31, R4, R5 and R51, further chiral centers in the positions 1, 2, 3 and 4. If A represents 5-7C-cycloalkylene, depending on the regiochemistry of the substitution, 2 further chiral centers also occur within the alkylene ring. Also, if A is 1-6C-alkylene and the 1-6C-alkylene radical is branched, additional chiral centers can occur within the alkylene radical.
• the invention therefore includes all conceivable pure diastereomers and pure enantiomers and their mixtures in any mixing ratio, including the racemates.
• the compounds of the formula I are preferred in which the hydrogen atoms in the positions 4 a and 10 b are cis to one another. Particularly preferred here are the pure cis diastereomers and the pure cis enantiomers and their mixtures in any mixing ratio and including the racemates.
• the enantiomers can be separated in a manner known per se (for example by preparation and separation of appropriate diastereoisomeric compounds). Preferably, a separation of enantiomers takes place at the stage of the starting compounds of the formula III
• enantiomerically pure starting compounds of the formula III can also be prepared via asymmetric syntheses.
• the stereochemistry within the alkylene radical is determined by the stereochemistry of the starting alkylene compounds used for the synthesis.
• the invention further relates to a process for the preparation of the compounds of the formula I, in which R1, R2, R3, R31, R4, R5, R51, A and R6 have the meanings indicated above, and their salts.
• the process comprises cyclocondensing compounds of the formula II
• R1, R2, R3, R31, R4, R5, R51, A and R6 have the meanings indicated above, and, if desired, then converting the compounds of the formula I obtained into their salts, or, if desired, then converting salts of the compounds of the formula I obtained into the free compounds.
• compounds of the formula I obtained can be converted into further compounds of the formula I by derivatization.
• the corresponding acids can be obtained from compounds of the formula I, in which R6 is an ester group, by acidic or alkaline hydrolysis
• the corresponding amides can be prepared by reaction with amines of the formula HN(R62)R63 or alternatively corresponding esters can be prepared by transesterification of esters of the formula I or by esterification of acids of the formula I.
• the reactions are expediently carried out analogously to the methods known to the person skilled in the art.
• Cyclocondensation is carried out in a manner known per se to the person skilled in the art according to Bischler-Napieralski (e.g. as described in J. Chem. Soc., 1956, 4280-4282) in the presence of a suitable condensing agent, such as, for example, polyphosphoric acid, phosphorus pentachloride phosphorus trichloride, phosphorus pentoxide, thionyl chloride or preferably phosphorous oxychloride, in a suitable inert solvent, e.g.
• a chlorinated hydrocarbon such as chloroform
• a cyclic hydrocarbon such as toluene or xylene
• another inert solvent such as acetonitrile
• an excess of condensing agent preferably at elevated temperature, in particular at the boiling temperature of the solvent or condensing agent used.
• the compounds of the formula III can be prepared, for example, from compounds of the formula IV
• Reduction is carried out in a manner known to the person skilled in the art, for example as described in J. Org. Chem. 1962, 27, 4426 or as described in the following examples.
• reduction is carried out by catalytic hydrogenation, e.g. in the presence of Raney nickel, in a lower alcohol such as methanol or ethanol at room temperature and under normal or elevated pressure.
• a catalytic amount of an acid such as, for example, hydrochloric acid, can be added to the solvent.
• the compounds of the formula III in which R1, R2, R3, R31 and R4 have the meanings indicated above and R5 and R51 together are an additional bond, can be prepared from the corresponding compounds of the formula IV by selective reduction of the nitro group in a manner known to the person skilled in the art, for example in the presence of Raney nickel in a lower alcohol as a solvent using hydrazine hydrate as a hydrogen donor.
• the compounds of the formula IV in which R1, R2, R3, R31 and R4 have the meanings indicated above and R5 and R51 are hydrogen, are either known or can be prepared from corresponding compounds of the formula IV, in which R5 and R51 together are an additional bond.
• the reaction can be carried out in a manner known to the person skilled in the art, preferably by hydrogenation in the presence of a catalyst, such as, for example, palladium on activated carbon, e.g. as described in J. Chem. Soc. (C), 1971, 1805-1808.
• R3, R31 and R4 have the abovementioned meanings.
• Cycloaddition is carried out here in a manner known to the person skilled in the art according to Diels-Alder, e.g. as described in J. Amer. Chem. Soc. 1957, 79, 6559 or in J. Org. Chem. 1952, 17, 581 or as described in the following examples.
• the compounds of the formulas V and VI are either known or can be prepared in a known manner.
• the compounds of the formula V can be prepared, for example, from corresponding compounds of the formula VII in a manner known to the person skilled in the art, as described, for example, in J. Chem. Soc. 1951, 2524 or in J. Org. Chem. 1944, 9, 170 or as described in the following examples.
• R1 and R2 have the meanings indicated above, are either known or can be prepared in a manner known to the person skilled in the art, as described, for example, in Ber. Dtsch. Chem. Ges. 1925, 58, 203.
• the isolation and purification of the substances according to the invention is carried out in a manner known per se, for example by distilling off the solvent in vacuo and recrystallizing the resulting residue from a suitable solvent or subjecting it to one of the customary purification methods, such as, for example column chromatography on suitable support material.
• Salts are obtained by dissolving the free compound in a suitable solvent, e.g. in a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol), which contains the desired acid or base, or to which the desired acid or base is then added.
• a suitable solvent e.g. in a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol), which contains the desired acid or base, or to which the desired acid or base is then added.
• the salts are obtained by filtering, reprecipitation, precipitation with a nonsolvent for the addition salt or by evaporation of the solvent.
• Salts obtained can be converted by alkalization or by acidification into the free compounds, which in turn can be converted into salts. In this manner, pharmacologically intolerable salts can be converted into pharmacologically to
• m.p. stands for melting point, h for hour(s), RT for room temperature, EF for empirical formula, MW for molecular weight, calc. for calculated, fnd for found.
• Elemental analysis calc.: C, 72.15; H, 8.33; N, 3.51.
• fnd C, 72.07; H, 8.22; N, 3.42.
• the compounds according to the invention have useful pharmacological properties which make them industrially utilizable.
• PDE selective cyclic nucleotide phosphodiesterase
• bronchial therapeutics for the treatment of airway obstructions on account of their dilating action but also on account of their respiratory rate- or respiratory drive-increasing action
• erectile disfunction on account of their vascular dilating action, but on the other hand especially for the treatment of disorders, in particular of an inflammatory nature, e.g.
• the compounds according to the invention are distinguished by a low toxicity, a good enteral absorption (high bioavailability), a large therapeutic breadth and the absence of significant side effects.
• the compounds according to the invention can be employed in human and veterinary medicine as therapeutics, where they can be used, for example, for the treatment and prophylaxis of the following illnesses;: acute and chronic (in particular inflammatory and allergen-induced) airway disorders of varying origin (bronchitis, allergic bronchitis, bronchial asthma); dermatoses (especially of proliferative, inflammatory and allergic type) such as psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, Lichen simplex, sunburn, pruritus in the anogenital area, alopecia areata, hypertropic scars, discoid lupus erythematosus, follicular and widespread pyodermias, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders; disorders which
• the invention further relates to a method for the treatment of mammals, including humans, which are suffering from one of the abovementioned illnesses.
• the method is characterized in that a therapeutically active and pharmacologically effective and tolerable amount of one or more of the compounds according to the invention is administered to the ill mammal.
• the invention further relates to the compounds according to the invention for use in the treatment and/or prophylaxis of illnesses, especially the illnesses mentioned.
• the invention also relates to the use of the compounds according to the invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the illnesses mentioned.
• the invention furthermore relates to medicaments for the treatment and/or prophylaxis of the illnesses mentioned, which contain one or more of the compounds according to the invention.
• the medicaments are prepared by processes which are known per se and familiar to the person skilled in the art.
• auxiliaries which are suitable for the desired pharmaceutical formulations on account of this expert knowledge.
• solvents for example antioxidants, dispersants, emulsifiers, preservatives, solubilizers or permeation promoters, can be used.
• the compounds according to the invention are preferably also administered by inhalation.
• these are either administered directly as a powder (preferably in micronized form) or by atomizing solutions or suspensions which contain them.
• 4 reference is made, for example, to the details in European Patent 163 965.
• the compounds according to the invention are in particular administered in the form of those medications which are suitable for topical application.
• suitable pharmaceutical formulations are, for example, powders, emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels or solutions.
• the medicaments according to the invention are prepared by processes known per se.
• the dosage of the active compounds is carried out in the order of magnitude customary for PDE inhibitors.
• Topical applications forms (such as ointments) for the treatment of dermatoses thus contain the active compounds in a concentration of, for example, 0.1-99%.
• the dose for administration by inhalation is customarily between 0.1 and 3 mg per day.
• the customary dose in the case of systemic therapy (p.o. or i.v.) is between 0.03 and 3 mg/kg per day.
• FMLP N-formyl-methionyl-leucyl-phenylatanine
• chemiluminescence Mc Phail L C, Strum S L, Leone P A and Sozzani S. The neutrophil respiratory burst mechanism.
• Coffey R G Marcel Decker, Inc., New York-Basel-Hong Kong
• Substances which inhibit chemiluminescene and cytokine secretion and the secretion of proinflammatory mediators on inflammatory cells are those which inhibit PDE 4.
• This isoenzyme of the phosphodiesterase families is particularly represented in granulocytes. Its inhibition leads to an increase in the intracellular cyclic AMP concentration and thus to the inhibition of cellular activation. PDE 4 inhibition by the substances according to the invention is thus a central indicator for the suppression of inflammatory processes.
• the activity test was carried out by the method of Bauer and Schwabe, which was adapted to microtiter plates (Naunyn-Schmiedeberg's Arch, Pharmacol. 1980, 311, 193-198).
• the PDE reaction is carried out in the first step.
• the resultant 5′-nucleotide is cleaved to give the uncharged nucleoside by a 5′-nucleotidase of the snake venom from Crotalus atrox.
• the nucleoside is separated from the remaining charged substrate on ion exchange columns. The columns are eluted with 2 ml of 30 mM ammonium formate (pH 6.0) directly into minivials to which 2 ml of scintillation fluid is additionally added for counting.
• inhibitory values determined for the compounds according to the invention [inhibitory concentration as —Iog IC 50 (mol/l)] follow from Table A below, in which the numbers of the compounds correspond to the numbers of the examples.

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Pulmonology (AREA)
• Dermatology (AREA)
• Neurology (AREA)
• Immunology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Hospice & Palliative Care (AREA)
• Rheumatology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Urology & Nephrology (AREA)
• Otolaryngology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Other In-Based Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=8227118

Family Applications (1)

Country Status (11)

Cited By (9)

Families Citing this family (6)

Citations (1)

Family Cites Families (2)

• 1998
  • 1998-07-18 PT PT98942571T patent/PT1000034E/pt unknown
  • 1998-07-18 AU AU90664/98A patent/AU9066498A/en not_active Abandoned
  • 1998-07-18 EP EP98942571A patent/EP1000034B1/en not_active Expired - Lifetime
  • 1998-07-18 DK DK98942571T patent/DK1000034T3/da active
  • 1998-07-18 WO PCT/EP1998/004476 patent/WO1999005112A1/en active IP Right Grant
  • 1998-07-18 SI SI9830300T patent/SI1000034T1/xx unknown
  • 1998-07-18 ES ES98942571T patent/ES2184318T3/es not_active Expired - Lifetime
  • 1998-07-18 AT AT98942571T patent/ATE224372T1/de not_active IP Right Cessation
  • 1998-07-18 JP JP2000504111A patent/JP2001510826A/ja not_active Withdrawn
  • 1998-07-18 US US09/462,507 patent/US6214839B1/en not_active Expired - Fee Related
  • 1998-07-18 DE DE69808099T patent/DE69808099T2/de not_active Expired - Fee Related

Patent Citations (1)

Also Published As

Similar Documents

Legal Events